Moorfields, Topcon, IoO announce partnership launch of Cascader

News
Article

Utilizing artificial intelligence (AI), Cascader is a new medical technology company that aims to transform the detection and management of eye disease.

3D render AI artificial intelligence technology CPU central processor unit chipset on the printed circuit board for electronic and technology concept select focus shallow depth of field (Image credit: ©Kaikoro/Adobe Stock)

(Image credit: ©Kaikoro/Adobe Stock)

In a strategic partnership, Moorfields Eye Hospital NHS Foundation Trust, the UCL Institute of Ophthalmology (IoO), and Topcon Health recently announced the launch of Casacder Limited.1

Utilizing artificial intelligence (AI), Cascader is a new medical technology company that aims to transform the detection and management of eye disease. Cascader also builds on the growing field of Oculomics – using advanced retinal imaging to identify insights into systemic conditions such as cardiovascular disease, neurodegeneration, and dementia, according to the press release.1

“We are proud to support the founding of Cascader,” said Peter Ridley, Chief Executive of Moorfields Eye Hospital, in a press release. “This new venture represents the next step in our commitment to translating world-class research into tangible benefits for patients and the NHS.”

This partnership between these global leaders in the ophthalmic field will utilize the AI research and translation knowledge of Moorfields and UCL IoO and the technical advancements of TopCon Healthcare. UCL Business (UCLB) also played an instrumental role in the set-up of Cascader.

Headquartered in London, Cascader’s long-term mission is to develop a portfolio of AI tools to support earlier and more accurate detection of eye diseases. Its initial focus will be on macular diseases such as age-related macular degeneration (AMD). This work builds on landmark work led by Moorfields and UCL IoO including the 2016 collaboration with Google DeepMind and the development of RETFound – the first foundation model in ophthalmology – published in Nature in 2023.

“Topcon is thrilled to partner with Moorfields and the UCL Institute of Ophthalmology on this groundbreaking initiative. Cascader reflects our shared vision of how AI and ocular data can reshape eyecare and enable new frontiers in precision medicine,” said Ali Tafreshi, Chief Executive Officer of Topcon Healthcare, said in a press release. “This collaboration supports the broader mission of connecting ocular data to better health outcomes – both within eyecare and beyond.”

Led by Moorfields, INSIGHT Health Data Research Hub will support Cascader. INSIGHT is the world’s largest ophthalmic imaging bioresource, comprised of more than 35 million retinal images linked to clinical metadata and enables secure, anonymized data access for approved researchers – further supported by AI infrastructure, curation services, and active patient involvement.

“At Cascader, our mission is to turn cutting-edge research into clinically robust, scalable solutions that improve lives,” said. Ege Ilicak, Chief Operating Officer and co-founder of Cascader.

“With deep experience in medical engineering, we’re focused on ensuring that our AI-driven tools meet the highest quality and regulatory standards, while integrating seamlessly into real-world workflows – supporting professionals and empowering patients.

Reference:
1. jgrodriguez. Moorfields Eye Hospital, UCL Institute of Ophthalmology and Topcon Healthcare, Inc. launch Cascader Limited to advance AI-driven eyecare and Oculomics. Topcon Healthcare. Published May 6, 2025. Accessed May 7, 2025. https://topconhealthcare.com/article/moorfields-eye-hospital-ucl-institute-of-ophthalmology-and-topcon-healthcare-inc-launch-cascader-limited-to-advance-ai-driven-eyecare-and-oculomics/

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.